产品
编 号：F303082
分子式：C24H26BrN3O3
分子量：484.39
分子式：C24H26BrN3O3
分子量：484.39
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
250
In-stock
10mg
400
In-stock
50mg
640
In-stock
100mg
1024
In-stock
结构图
CAS No: 27848-84-6
产品详情
生物活性：
Nicergoline, an ergoline derivative ester of bromonicotinic acid, is a potent, selective and orally active antagonist of α1A-adrenoceptor. Nicergoline has vasodilator effects. Nicergoline also has ameliorative effects on cognitive function in mouse models of Alzheimer's disease.
体内研究：
Nicergoline (10 mg/kg; i.v. once daily for 60 d) improves impaired neurogenesis and cognitive competence in mice with Alzheimer's disease.Nicergoline (10 mg/kg; i.v. once daily for 60 d) inhibits apoptosis, inflammation and oxidative stress in hippocampal cells, and regulates the activity of hippocampal cells through the PI3K/AKT signaling pathway in mice.Animal Model:3×Tg-AD mice (male, 28-35 g, 6 weeks) with the Alzheimer's disease
Dosage:10 mg/kg
Administration:I.v. once daily for 60 days
Result:Improved neurogenesis and cognitive competence.Decreased the degree of dementia.Downregulated pathogenic Aβ-42 and -40 peptides and APP in the hippocampi.Increased Levels of the neuroprotective forkhead box protein P2 (Foxp2), Src homology 2-containing inositol phosphatase (SxIP) and end-binding proteins (EB) in the hippocampi.Exhibited marked differences in the dispersion of the pyramidal cell layer between the nicergoline-treated and control groups.
体外研究：
Nicergoline (0.3-30 μM; 24 h) attenuates activated microglia- and astrocytes-induced neuronal cell death.Nicergoline (0.3-30 μM; 48 h) suppresses the production of proinflammatory cytokines and superoxide anion by activated microglia.
Nicergoline, an ergoline derivative ester of bromonicotinic acid, is a potent, selective and orally active antagonist of α1A-adrenoceptor. Nicergoline has vasodilator effects. Nicergoline also has ameliorative effects on cognitive function in mouse models of Alzheimer's disease.
体内研究：
Nicergoline (10 mg/kg; i.v. once daily for 60 d) improves impaired neurogenesis and cognitive competence in mice with Alzheimer's disease.Nicergoline (10 mg/kg; i.v. once daily for 60 d) inhibits apoptosis, inflammation and oxidative stress in hippocampal cells, and regulates the activity of hippocampal cells through the PI3K/AKT signaling pathway in mice.Animal Model:3×Tg-AD mice (male, 28-35 g, 6 weeks) with the Alzheimer's disease
Dosage:10 mg/kg
Administration:I.v. once daily for 60 days
Result:Improved neurogenesis and cognitive competence.Decreased the degree of dementia.Downregulated pathogenic Aβ-42 and -40 peptides and APP in the hippocampi.Increased Levels of the neuroprotective forkhead box protein P2 (Foxp2), Src homology 2-containing inositol phosphatase (SxIP) and end-binding proteins (EB) in the hippocampi.Exhibited marked differences in the dispersion of the pyramidal cell layer between the nicergoline-treated and control groups.
体外研究：
Nicergoline (0.3-30 μM; 24 h) attenuates activated microglia- and astrocytes-induced neuronal cell death.Nicergoline (0.3-30 μM; 48 h) suppresses the production of proinflammatory cytokines and superoxide anion by activated microglia.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备